Lantheus (NASDAQ:LNTH) Hits New 12-Month High – What’s Next?

Lantheus Holdings, Inc. (NASDAQ:LNTH) hit a new 52-week high on Wednesday . The company traded as high as $96.28 and last traded at $96.23, with a volume of 1230208 shares. The stock had previously closed at $94.07.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LNTH. Mizuho boosted their target price on shares of Lantheus from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Truist Financial reaffirmed a “buy” rating and issued a $115.00 target price (up from $98.00) on shares of Lantheus in a research note on Monday. Finally, Citizens Jmp boosted their target price on shares of Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a research note on Friday, May 8th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.71.

Lantheus Stock Performance

The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. The firm has a market capitalization of $6.27 billion, a P/E ratio of 23.19 and a beta of -0.08. The stock’s 50 day moving average is $80.84 and its two-hundred day moving average is $69.66.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. Lantheus’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 4.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Osterweis Capital Management Inc. acquired a new position in Lantheus during the second quarter valued at approximately $36,000. Hantz Financial Services Inc. grew its holdings in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 396 shares during the period. First Horizon Corp acquired a new position in Lantheus during the third quarter valued at approximately $26,000. Smartleaf Asset Management LLC boosted its holdings in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares during the period. Finally, Bessemer Group Inc. boosted its holdings in shares of Lantheus by 221.3% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 354 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.